**Relugolix** HERO

Relugolix HERO

## PRELIMINARY SCORE

**CURATIVE**

**NON-CURATIVE**

NI

## ADJUSTMENTS

**Quality of life**

QoL data pending

**Serious and disabling adverse effects**

Reduced toxicity

**Other adjustments**

**Relugolix HERO**

## FINAL SCORE

**CURATIVE**

Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**

Overall Survival

Progression-Free Survival

Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Tumour type: Genitourinary Cancers
Therapeutic Indication: Adult patients with advanced hormone-sensitive prostate cancer
Experimental Arm: Relugolix
Control Arm: Leuprolide

© 2023 | **European Society for Medical Oncology** | ESMO - MCBS 1.1 | All rights reserved worldwide.